Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab, and AG Regimen in Advanced Cholangiocarcinoma
NCT07328802Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in cholangiocarcinoma (CCA), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07328802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328802.